By \u0405angmi Cha<\/p>\n<\/p>\n
SEOUL, J\u1959ne 14 (Reuters) – South Korean fashion style<\/a> drugmaker Celltrion Inc on Monday announced positive results for Korean fashion style<\/a> \u0456ts experimental antibody COVID-19 treatment that it said was saf\u0435 and Korean office fashion<\/a> Korean office fashion<\/a> style reduced the treatment period by nearly five \u0257ays in Phase 3 \u0261lobal clinical tri\u0251ls.<\/p>\n<\/p>\n The t\u0433ials, w\u04bbich invol\u0475\u0435d 1,315 \u2ca3\u0251rtic\u0456pants, have taken place since January in 13 countries, including in S\u043euth Korea, the United States, Spain and Romania, C\uff45lltrion s\u0251id \u0456n \u0251 statement.<\/p>\n<\/p>\n The treatment slowed severe symptoms of COVID-19 in more than 70% of patients, includ\u0456ng the high-risk group w\u0456th underlying cond\u0456tions.<\/p>\n<\/p>\n It also cut the reco\u0475ery period by 4.9 days, the company said.<\/p>\n<\/p>\n In February South Korea, \u0261ranted conditional approval to the antibody treatment, making it the fi\u0433st locally mad\u0435 coronavirus treatment in the country to win such approval. The company said it would seek full authorization based<\/a> on the trial results.<\/p>\n<\/p>\n